The Federal Trade Commission unveiled its proposed updates to the FTC’s Guides Concerning the Use of Endorsements and Testimonials in Advertising at its recent open meeting on May 19, 2022, followed by publication of a notice requesting public comments.
The National Advertising Division of BBB National Programs has recommended that The Procter & Gamble Company discontinue the claim that Olay Premium body wash “improves skin 3X better” than the leading body wash.
The Federal Trade Commission (FTC) has fined online fashion retailer Fashion Nova $4.2 million to settle allegations that the company blocked negative reviews of its products from being posted on its website.
In its latest decision regarding incentivized consumer reviews, the National Advertising Division of BBB National Programs ruled that a general disclosure is not sufficient to disclose incentivized consumer reviews on a website when there are multiple reviews.
In a recent case, the National Advertising Division (NAD) of BBB National Programs discussed the use of emojis in advertising and whether they can constitute claims.
The Federal Trade Commission has finalized the Made in USA Labeling Rule, which codifies its long-standing enforcement policy requiring that marketers making unqualified Made in USA claims on labels be able to prove that their products are “all or virtually all” made in the United ...
Lina Khan was sworn in as Chair of the Federal Trade Commission on June 15, 2021.
A panel of the National Advertising Review Board has recommended that Colgate-Palmolive Company discontinue the claim that Colgate Optic White Renewal toothpaste “removes 10 years of yellow stains”.
In another decision involving teeth whitening claims, the National Advertising Division of BBB National Programs determined that The Procter & Gamble Company substantiated claims that its Crest Whitening Emulsions provides “better” or “100% whiter” results.
The medical director of Golden Sunrise Nutraceutical, Inc., agreed to settle Federal Trade Commission charges that he took part in deceptively advertising a $23,000 treatment plan as a scientifically proven way to treat COVID-19.